 |
 Video: What is a Stock Split?
|
|
|
| FibroGen is a biopharmaceutical company that developes and commercializes a pipeline of therapeutics. Co. applies its capability in hypoxia-inducible factor (HIF) biology and connective tissue growth factor (CTGF) biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, Co.'s main product, is an inhibitor of HIF-prolyl hydroxylase activity that acts by stimulating the body's natural pathway of erythropoiesis or red blood cell production. Pamrevlumab is Co.'s human monoclonal antibody that inhibits the activity of CTGF for the treatment of idiopathic pulmonary fibrosis, locally advanced unresectable pancreatic cancer, and Duchenne muscular dystroph. According to our FibroGen stock split history records, FibroGen has had 0 splits. | |
|
FibroGen (FGEN) has 0 splits in our FibroGen stock split history database.
Looking at the FibroGen stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into FibroGen shares, starting with a $10,000 purchase of FGEN, presented on a split-history-adjusted basis factoring in the complete FibroGen stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
11/17/2014 |
|
| End date: |
04/22/2024 |
|
| Start price/share: |
$23.81 |
|
| End price/share: |
$1.14 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-95.21% |
|
| Average Annual Total Return: |
-27.54% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$478.99 |
|
| Years: |
9.43 |
|
|
|
|
|
